AbCellera Biologics(ABCL),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

ABCL AbCellera Biologics

Market Closed 03-13 16:00:00 EDT

3.49

+0.02

+0.58%

盘后3.49

+0.00+0.03%

19:51 EDT

High3.66	Low3.43	Vol2.07M
Open3.52	D1 Closing3.47	Amplitude6.48%
Mkt Cap1.06B	Tradable Cap707.60M	Total Shares303.16M
T/O7.24M	T/O Rate1.02%	Tradable Shares202.75M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"ABCL","market":"US","secType":"STK","nameCN":"AbCellera Biologics","latestPrice":3.49,"timestamp":1773432000000,"preClose":3.47,"halted":0,"volume":2067012,"hourTrading":{"tag":"盘后","latestPrice":3.491,"preClose":3.49,"latestTime":"19:51 EDT","volume":16799,"amount":58875.6331,"timestamp":1773445894241,"change":0.001,"changeRate":0.000287,"amplitude":0.017192},"delay":0,"changeRate":0.005763688760806921,"floatShares":202749853,"shares":303160487,"eps":-0.49,"marketStatus":"Market Closed","change":0.02,"latestTime":"03-13 16:00:00 EDT","open":3.52,"high":3.655,"low":3.43,"amount":7241676.912021601,"amplitude":0.064841,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.49,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1773648000000},"marketStatusCode":7,"adr":0,"listingDate":1607662800000,"exchange":"NASDAQ","adjPreClose":3.47,"preHourTrading":{"tag":"盘前","latestPrice":3.52,"preClose":3.47,"latestTime":"09:29 EDT","volume":14390,"amount":50323.74387,"timestamp":1773408570056,"change":0.05,"changeRate":0.014409,"amplitude":0.025937},"postHourTrading":{"tag":"盘后","latestPrice":3.491,"preClose":3.49,"latestTime":"19:51 EDT","volume":16799,"amount":58875.6331,"timestamp":1773445894241,"change":0.001,"changeRate":0.000287,"amplitude":0.017192},"volumeRatio":0.6835447633776833,"impliedVol":0.9527,"impliedVolPercentile":0.4024},"requestUrl":"/m/hq/s/ABCL","defaultTab":"news","newsList":[{"id":"2618593908","title":"A Look At AbCellera Biologics (ABCL) Valuation After Annual Earnings Reveal Higher Revenue And A Narrower Net Loss","url":"https://stock-news.laohu8.com/highlight/detail?id=2618593908","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618593908?lang=en_us&edition=fundamental","pubTime":"2026-03-10 17:17","pubTimestamp":1773134266,"startTime":"0","endTime":"0","summary":"AbCellera Biologics (ABCL) is back in focus after releasing full year 2025 results, reporting revenue of US$75.13 million compared with US$28.83 million a year earlier and a net loss of US$146.41 million compared with US$162.86 million.\nSee our latest analysis for AbCellera Biologics.\nAbCellera Biologics’ latest earnings drop comes after a mixed period for investors, with a 1-month share price return of 11.39% but a 3-year total shareholder return decline of 52.56% and a 5-year total...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/9551728-choice2-main-header/1585186774276","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/9551728-choice2-main-header/1585186774276"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-abcl/abcellera-biologics/news/a-look-at-abcellera-biologics-abcl-valuation-after-annual-ea","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-abcl/abcellera-biologics/news/a-look-at-abcellera-biologics-abcl-valuation-after-annual-ea","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["ABCL"],"gpt_icon":0},{"id":"2616439967","title":"Major Investor Quietly Ramps Up Stake in AbCellera Biologics","url":"https://stock-news.laohu8.com/highlight/detail?id=2616439967","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616439967?lang=en_us&edition=fundamental","pubTime":"2026-03-03 10:07","pubTimestamp":1772503635,"startTime":"0","endTime":"0","summary":"New insider activity at AbCellera Biologics ( ($ABCL) ) has taken place on March 2, 2026. Significant shareholder Thermopylae Holdings Ltd. has boo...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/insider-trading/major-investor-quietly-ramps-up-stake-in-abcellera-biologics-insider-trading-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/insider-trading/major-investor-quietly-ramps-up-stake-in-abcellera-biologics-insider-trading-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4121","BK4535","ABCL"],"gpt_icon":0},{"id":"1116759654","title":"Stock Track | AbCellera Biologics Soars 5.26% Intraday on Major Shareholder Acquisition","url":"https://stock-news.laohu8.com/highlight/detail?id=1116759654","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1116759654?lang=en_us&edition=fundamental","pubTime":"2026-03-03 04:50","pubTimestamp":1772484640,"startTime":"0","endTime":"0","summary":"AbCellera Biologics' stock surged 5.26% during intraday trading on Monday, following news of increased ownership by a significant investor.The price movement appears to be driven by a filing...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["ABCL"],"gpt_icon":0},{"id":"2614989901","title":"Insiders Quietly Double Down on AbCellera Biologics in Bold Buying Spree","url":"https://stock-news.laohu8.com/highlight/detail?id=2614989901","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614989901?lang=en_us&edition=fundamental","pubTime":"2026-02-28 10:07","pubTimestamp":1772244458,"startTime":"0","endTime":"0","summary":"New insider activity at AbCellera Biologics ( ($ABCL) ) has taken place on February 27, 2026. AbCellera Biologics has seen notable insider buying a...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/insider-trading/insiders-quietly-double-down-on-abcellera-biologics-in-bold-buying-spree-insider-trading-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/insider-trading/insiders-quietly-double-down-on-abcellera-biologics-in-bold-buying-spree-insider-trading-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ABCL","SHAP.U","BK4535","BK4121"],"gpt_icon":0},{"id":"1127244178","title":"Stock Track | AbCellera Biologics Soars 5.26% in After-Hours on Insider Buying by Major Shareholder and CFO","url":"https://stock-news.laohu8.com/highlight/detail?id=1127244178","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1127244178?lang=en_us&edition=fundamental","pubTime":"2026-02-28 07:54","pubTimestamp":1772236484,"startTime":"0","endTime":"0","summary":"AbCellera Biologics' stock surged 5.26% in the after-hours session on Friday, following significant insider purchases reported earlier in the day.The movement appears to be driven by filings showing...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["ABCL"],"gpt_icon":0},{"id":"2614867803","title":"Thermopylae Holdings Ltd. Acquires AbCellera Biologics Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2614867803","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614867803?lang=en_us&edition=fundamental","pubTime":"2026-02-28 05:28","pubTimestamp":1772227687,"startTime":"0","endTime":"0","summary":"Thermopylae Holdings Ltd., a 10% owner, reported an acquisition of 177,457 common shares of AbCellera Biologics Inc. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Abcellera Biologics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on February 27, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260227:nNDL9lkG8l:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ABCL","BK4121","BK4535"],"gpt_icon":0},{"id":"2614786103","title":"AbCellera CFO Andrew Booth Acquires Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2614786103","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614786103?lang=en_us&edition=fundamental","pubTime":"2026-02-28 03:49","pubTimestamp":1772221754,"startTime":"0","endTime":"0","summary":"Andrew Booth, Chief Financial Officer, reported an acquisition of common shares of AbCellera Biologics Inc. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Abcellera Biologics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on February 27, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260227:nNDL2fmzBs:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"AbCellera CFO Andrew Booth Acquires Common Shares","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4121","BK4535","ABCL"],"gpt_icon":0},{"id":"2614099694","title":"Abcellera Warns Growing Generative AI Use Raises Cybersecurity, Privacy, and Operational Risks","url":"https://stock-news.laohu8.com/highlight/detail?id=2614099694","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614099694?lang=en_us&edition=fundamental","pubTime":"2026-02-26 14:00","pubTimestamp":1772085648,"startTime":"0","endTime":"0","summary":"Abcellera Biologics, Inc. (ABCL) has disclosed a new risk, in the Cyber Security category. Abcellera Biologics, Inc. faces growing risk as it and i...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/abcellera-warns-growing-generative-ai-use-raises-cybersecurity-privacy-and-operational-risks?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/abcellera-warns-growing-generative-ai-use-raises-cybersecurity-privacy-and-operational-risks?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ABCL","BK4535","BK4121","BK4097","NTSK"],"gpt_icon":0},{"id":"2614230065","title":"AbCellera (ABCL) Earnings Call: Liquidity, Risks, Catalysts","url":"https://stock-news.laohu8.com/highlight/detail?id=2614230065","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614230065?lang=en_us&edition=fundamental","pubTime":"2026-02-26 08:26","pubTimestamp":1772065584,"startTime":"0","endTime":"0","summary":"Abcellera Biologics, Inc. (($ABCL)) has held its Q4 earnings call. Read on for the main highlights of the call. AbCellera Biologics’ latest earning...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/abcellera-abcl-earnings-call-liquidity-risks-catalysts?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/abcellera-abcl-earnings-call-liquidity-risks-catalysts?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ABCL"],"gpt_icon":0},{"id":"2614035340","title":"Abcellera Biologics Inc : Piper Sandler Cuts Target Price to $12 From $16","url":"https://stock-news.laohu8.com/highlight/detail?id=2614035340","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614035340?lang=en_us&edition=fundamental","pubTime":"2026-02-25 22:40","pubTimestamp":1772030449,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260225:nFWN3ZL1SE:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ABCL","BK4535","BK4121"],"gpt_icon":0},{"id":"2614701768","title":"What Sparked AbCellera Biologics To Soar Over 9% After Hours","url":"https://stock-news.laohu8.com/highlight/detail?id=2614701768","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614701768?lang=en_us&edition=fundamental","pubTime":"2026-02-25 16:51","pubTimestamp":1772009491,"startTime":"0","endTime":"0","summary":"AbCellera Biologics shares jumped 9.3% after hours to $3.52 following an 83% earnings beat in Q4 2025.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/markets/equities/26/02/50841437/what-sparked-abcellera-biologics-to-soar-over-9-after-hours","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RSI","ABCL","BK4121","BK4535","BK4150"],"gpt_icon":0},{"id":"2614372335","title":"AbCellera Q4 revenue beats expectations","url":"https://stock-news.laohu8.com/highlight/detail?id=2614372335","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614372335?lang=en_us&edition=fundamental","pubTime":"2026-02-25 05:21","pubTimestamp":1771968068,"startTime":"0","endTime":"0","summary":"AbCellera Q4 revenue beats expectationsOverviewBiotech firm's Q4 revenue beat analyst expectationsNet loss for FY 2025 narrowed compared to previous yearCompany advanced multiple programs into clinica","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260224:nL1N3ZK1AI:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4535","BK4121","ABCL"],"gpt_icon":0},{"id":"2614728006","title":"AbCellera Biologics Q4 EPS $(0.03) Beats $(0.17) Estimate, Sales $44.900M Beat $6.351M Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2614728006","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614728006?lang=en_us&edition=fundamental","pubTime":"2026-02-25 05:20","pubTimestamp":1771968039,"startTime":"0","endTime":"0","summary":"AbCellera Biologics (NASDAQ:ABCL) reported quarterly losses of $(0.03) per share which beat the analyst consensus estimate of $(0.17) by 82.04 percent. This is a 75 percent increase over losses of $(0.12) per share from","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/02/50834439/abcellera-biologics-q4-eps-0-03-beats-0-17-estimate-sales-44-900m-beat-6-351m-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"AbCellera Biologics Q4 EPS $(0.03) Beats $(0.17) Estimate, Sales $44.900M Beat $6.351M Estimate","news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ABCL"],"gpt_icon":0},{"id":"2614827723","title":"AbCellera reports FY25 EPS (49c) vs. (55c) last year","url":"https://stock-news.laohu8.com/highlight/detail?id=2614827723","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614827723?lang=en_us&edition=fundamental","pubTime":"2026-02-25 05:15","pubTimestamp":1771967721,"startTime":"0","endTime":"0","summary":"Reports FY25 revenue $75.1M vs. $28.8M last year. “In 2025, AbCellera (ABCL) successfully delivered on all its corporate priorities, transitioned t...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/abcellera-reports-fy25-eps-49c-vs-55c-last-year-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/abcellera-reports-fy25-eps-49c-vs-55c-last-year-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4535","ABCL","BK4121"],"gpt_icon":0},{"id":"2614740034","title":"AbCellera FY 2025 revenue jumps 2.6x to USD 75.1 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2614740034","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614740034?lang=en_us&edition=fundamental","pubTime":"2026-02-25 05:05","pubTimestamp":1771967156,"startTime":"0","endTime":"0","summary":"AbCellera reported FY 2025 total revenue of USD 75.1 million, up 160.7%, and a net loss of USD 146.4 million, or USD  per share . R&D expenses were USD 186.8 million and SG&A expenses were USD 83.2 million. The company ended FY 2025 with USD 561.0 million in cash, cash equivalents and marketable securities and about USD 135.0 million in available non-dilutive government funding, for total available liquidity of about USD 700.0 million. In Q4 2025, revenue was USD 44.9 million, primarily related to an upfront settlement payment from patent litigation, representing 60% of FY 2025 revenue; operating expenses were USD 73.4 million and net loss was USD 8.9 million, or USD  per share . On the business side, AbCellera said it transitioned to a clinical-stage biotech company and completed multi-year platform investments, including opening a clinical manufacturing facility. ABCL635 entered the Phase 2 portion of its Phase 1/2 trial at the end of FY 2025, ABCL575 progressed through Phase 1, and ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260224:nNDL82Pvq7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4535","ABCL","BK4121"],"gpt_icon":0},{"id":"2614740754","title":"BRIEF-AbCellera Q4 Revenue USD 44.9 Million Vs. IBES Estimate USD 6.06 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2614740754","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614740754?lang=en_us&edition=fundamental","pubTime":"2026-02-25 05:05","pubTimestamp":1771967147,"startTime":"0","endTime":"0","summary":"BRIEF-AbCellera Q4 Revenue USD 44.9 Million Vs. IBES Estimate USD 6.06 Million\n\n\nFeb 24 (Reuters) - AbCellera Q4 net income USD -8.9 million.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260224:nPLX33FA9C:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4121","BK4535","ABCL"],"gpt_icon":0},{"id":"2614374074","title":"Press Release: AbCellera Reports Full Year 2025 Business Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2614374074","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614374074?lang=en_us&edition=fundamental","pubTime":"2026-02-25 05:05","pubTimestamp":1771967100,"startTime":"0","endTime":"0","summary":"AbCellera  today announced financial results for the full year 2025. All financial information in this press release is reported in U.S. dollars, unless otherwise indicated.\"In 2025, AbCellera successfully delivered on all its corporate priorities, transitioned to a clinical-stage biotech company, and ended the year with approximately $700 million in available liquidity to execute on our strategy,\" said Carl Hansen, Ph.D., founder and CEO of AbCellera. \"We entered 2026 with a fully built platform, a growing pipeline with multiple potential first-in-class programs and important near-term clinical readouts, and sufficient liquidity to fund well beyond the next three years of pipeline investments.\". --  Generated a net loss of $146.4 million, compared to a net loss of. --  Advanced two programs, ABCL635 and ABCL575, into clinical trials:. --  ABCL635 entered the Phase 2 portion of a Phase 1/2 clinical. --  ABCL575 is progressing through a Phase 1 clinical trial.In 2025, AbCellera started ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ABCL","BK4535","BK4121"],"gpt_icon":0},{"id":"2613790840","title":"Calendar of U.S. Earnings Expected in the Week Ahead","url":"https://stock-news.laohu8.com/highlight/detail?id=2613790840","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613790840?lang=en_us&edition=fundamental","pubTime":"2026-02-24 19:00","pubTimestamp":1771930800,"startTime":"0","endTime":"0","summary":"Major companies tentatively scheduled to report quarterly earnings in the week ahead, with earnings estimates provided by FactSet Research Systems Inc.Albany Intl Corp. Class A                        4Q       .61        BMO. Bank of Nova Scotia                              1Q      1.43    6:15 AM. Bowhead Specialty Hldgs Inc.                     4Q       .44    7:00 AM. Clean Energy Fuels Corp.                        4Q      (.05)   4:05 PM. Controladora Vuela Comp de Aviacion             4Q       .20        AMC","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CBLL","CYTK","ATRO","HSBC","AII","ARVN","ASR","CAVA","CWH","CGBD","CLNE","CSGP","DAWN","CDNA","AS","BNS","ELAN","AWI","AXGN","BOW","APLS","EXPD","EOG","BXC","ACHC","BRSL","CECO","AXON","ECG","DOCN","AMT","BBIO","ESTA","ABCL","CLVT","ACAD","ATEC","EVH","FERG","CCC","DRS","CORT","EXLS","ESPR","DDS","AHCO","CIFR","ADTN","AIN"],"gpt_icon":1},{"id":"2610668439","title":"AbCellera Biologics to Present at Major Investor Conferences","url":"https://stock-news.laohu8.com/highlight/detail?id=2610668439","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610668439?lang=en_us&edition=fundamental","pubTime":"2026-02-12 05:06","pubTimestamp":1770844003,"startTime":"0","endTime":"0","summary":"AbCellera Biologics Inc.  will participate in several upcoming investor conferences in March and April 2026. The company is scheduled to present at the TD Cowen 46th Annual Health Care Conference on March 4, 2026, the KeyBanc Capital Markets Healthcare Forum on March 17, 2026, and the Bloom Burton & Co. Healthcare Investor Conference on April 21-22, 2026. Live audio webcasts of each presentation will be accessible through a link posted on AbCellera's Investor Relations website closer to the date, with replays available through the same link following the presentations.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Abcellera Biologics Inc. published the original content used to generate this news brief via Business Wire  on February 11","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260211:nNDLb0q3Qm:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4121","BK4535","ABCL"],"gpt_icon":0},{"id":"2610666389","title":"11 Stocks That Have Cratered and Look Like Buys -- Barrons.com","url":"https://stock-news.laohu8.com/highlight/detail?id=2610666389","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610666389?lang=en_us&edition=fundamental","pubTime":"2026-02-10 03:22","pubTimestamp":1770664920,"startTime":"0","endTime":"0","summary":"Sometimes, an opportunity to buy something is hiding in plain sight. That is a distinct possibility today, considering the tons of stocks that have crashed recently.Enormous drops in stocks have historically provided some of the best buying opportunities. When a concern emerges, prices fall to levels that fully reflect the worry, whether the risk that caused the selloff materializes or not. That sets the shares up to benefit from any improvement in sentiment.Elsewhere, companies that provide private loans and equity financing, via private investment funds, have seen their stocks tank. Even shares of the investment bank Jefferies, which owns a stake in a hedge fund that had exposure to private credit, are down 14% from a multimonth high hit in September. To make the list, short interest had to be in the 65th percentile of the historic range for each company, or higher, meaning that the st","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0124676726.USD","LU2125154778.USD","LU1267930730.SGD","BK4598","LU1323610961.USD","LU0795875086.SGD","LU2347655156.SGD","LU2106854487.HKD","LU1974910355.USD","LU1923622291.USD","LU0266013472.USD","LU0251132253.USD","LU0353189680.USD","IE00BFSS8Q28.SGD","LU2361044865.SGD","LU2362541273.HKD","IE00BZ9MQY76.HKD","LU0130102774.USD","LU0053666078.USD","SG9999001176.USD","LU0965509283.SGD","LU1506573853.SGD","BK4503","LU0648001328.SGD","LU1316542783.SGD","LU2491049909.HKD","LU0708994859.HKD","LU2023251221.USD","LU0289739699.SGD","BK4023","LU1366333091.USD","LU1804176565.USD","LU0683600562.USD","BK4534","LU0114720955.EUR","LU0079474960.USD","OWL","LU2125154935.USD","LU1548497426.USD","LU0820561818.USD","LU1064131342.USD","IE00BQXX3F31.USD","BK4533","LU2236285917.USD","LU0077335932.USD","BK4532","IE00BJJMRZ35.SGD","LU0256863811.USD","SGXZ81514606.USD","LU0342679015.USD","LU0149725797.USD","LU2362540622.SGD","LU1989771016.USD","BK4097","LU1951200564.SGD","BK4527","IE00BJJMRX11.SGD","LU0511384066.AUD","LU0976567544.SGD","ABCL","BK4550","LU0354030511.USD","LU1551013342.USD","LU0157215616.USD","LU2237438978.USD","LU0238689110.USD","LU2458330243.SGD","IE0002270589.USD","LU2552382215.SGD","IE0005OL40V9.USD","LU0345770993.USD","LU0128525689.USD","LU0942090050.USD","LU2756315664.SGD","LU1267930227.SGD","BK4579","LU1917777945.USD","BK4585","LU0965509010.AUD","ABSI","LU1061106388.HKD","LU2265009873.SGD","LU0980610538.SGD","LU0719512351.SGD","IE0004445239.USD","LU0122379950.USD","LU0320765059.SGD","LU2028103732.USD","LU1778281490.HKD","LU0672654240.SGD","IE00BJTD4V19.USD","IE0004445015.USD","LU1496350502.SGD","IE00BFSS7M15.SGD","LU0130517989.USD","SG9999002224.SGD","LU0861579265.USD","SG9999002232.USD","LU0787776722.HKD","LU0949170772.SGD","LU1989764748.USD","IE00B1XK9C88.USD","LU1674673691.USD","LU1069347547.HKD","LU1854104046.USD","LU0868494617.USD","LU0496365809.HKD","LU0267386448.USD","IE00BMPRXN33.USD","LU0345770308.USD","LU0211327993.USD","BK4588","IE00B2B36J28.USD","LU0029864427.USD","LU1988902786.USD","IE00BYQQ9H92.USD","IE00BFXG0V08.USD","LU0553294199.USD","LU1633808545.USD","IE00BKPKM429.USD","LU0889565833.HKD","BK4543","LU2461242641.AUD","LU0069063385.USD","SG9999014914.USD","IE00BWXC8680.SGD","LU2023250504.SGD","SDGR","IE00B19Z8X17.USD","LU0158827948.USD","SGXZ57979304.SGD","IE00B4R5TH58.HKD","LU1934455194.USD","LU0082616367.USD","CRM","LU0742534661.SGD","LU2357305700.SGD","LU2264538146.SGD","LU1914381329.SGD","LU2133065610.SGD","LU2210149790.SGD","LU0943347566.SGD","IE00BQXX3D17.EUR","LU1037948541.HKD","LU1496350171.SGD","IE00BMPRXR70.SGD","LU1551013425.SGD","BK4592","SG9999014906.USD","LU0128525929.USD","SGXZ51526630.SGD","LU0127658192.USD","LU1066051498.USD","LU0316494557.USD","LU2125909593.SGD","LU2111349929.HKD","LU0265550359.USD","BK4554","LU1116320737.USD","LU1261432733.SGD","LU0048584097.USD","LU0353189763.USD","LU0203345920.USD","LU2381873111.SGD","BK4607","LU0868494708.USD","LU1934455863.HKD","LU1201861249.SGD","LU2125909759.SGD","LU2211815571.USD","LU1623119135.USD","LU0203347892.USD","LU0345774631.USD","LU1720051108.HKD","LU2242649171.HKD","LU0889566641.SGD","LU0011850046.USD","ADBE","LU1803068979.SGD","LU0795875169.SGD","LU0097036916.USD","IE00B7KXQ091.USD","LU0198837287.USD","LU0289739343.SGD","LU0820562030.AUD","LU2458330169.SGD","LU2317271919.USD","UNHW","LU0456855351.SGD","LU2087625088.SGD","LU2361044949.HKD","LU0058720904.USD","IE00BJJMRY28.SGD","LU1066053197.SGD","LU1153585028.USD","LU2286300806.USD","LU1674673428.USD","IE00B7SZLL34.SGD","LU0689626769.HKD","IE00BKVL7J92.USD","LU2023250843.SGD","IE00B1BXHZ80.USD","LU1989764664.SGD","LU1720051017.SGD","LU0109391861.USD","LU0823416689.USD","LU2271345857.HKD","LU1116320901.HKD","LU1235294995.USD","IE00B19Z3B42.SGD","IE00BZ1G4Q59.USD","LU2247934214.USD","IE0009356076.USD","SG9999018865.SGD","LU2468319806.SGD","LU1023059063.AUD","LU0661504455.SGD","BK4567","BK4528","LU2433249047.HKD","LU0314104364.USD","LU0211328371.USD","LU0289961442.SGD","LU1854103824.USD","LU2362541513.USD","LU1267930490.SGD","LU1951198990.SGD","LU0545039389.USD","SG9999018857.SGD","LU1057294990.SGD","IE00BJTD4N35.SGD","SGXZ31699556.SGD","LU1732800096.USD","LU0432979614.USD","LU0187121727.USD","RXRX","LU1037948897.HKD","SG9999000418.SGD","LU0310799852.SGD","LU2552382132.HKD","SG9999013999.USD","IE00BSNM7G36.USD","BK4566","LU0094547139.USD","LU0642271901.SGD","LU1815333072.USD","LU1983299246.USD","IE00B894F039.SGD","IE0009355771.USD","LU0006306889.USD","LU1046421795.USD","LU2279689827.SGD","LU2361045086.USD","IE00B19Z9Z06.USD","BK4608","LU0823434583.USD","NOW","IE00BJT1NW94.SGD","SAIL","LU2244417387.USD","IE00B4JS1V06.HKD","LU2756315318.SGD","IE0002141913.USD","LU0251131958.USD","LU0348723411.USD","LU0957791311.USD","LU1670627923.USD","LU0823434740.USD","LU1791710582.SGD","LU2125909247.SGD","LU1814569148.SGD","LU1066051811.HKD","LU0820561909.HKD","LU0528227936.USD","LU0170899867.USD","SG9999014898.SGD","LU0234570918.USD","LU0048573561.USD","LU1084165304.USD","SGXZ99366536.SGD","LU0354030438.USD","BK4613","LU0057025933.USD","LU2112291526.USD","UNH","LU0965508806.USD","IE00BQXX3C00.GBP","LU0965509101.SGD","LU0106261372.USD","LU1119994496.HKD","LU1989772840.SGD","LU1934455277.USD","LU0234572021.USD","LU2063271972.USD","IE000M9KFDE8.USD","LU0310800379.SGD","BK4535","BK4538","LU0211326755.USD","LU1712237335.SGD","UNHG","LU2125909916.SGD","LU0345774391.USD","LU0912757837.SGD","LU0310800965.SGD","IE00BFXG1179.USD","LU0557290698.USD","LU1670628061.USD","LU0708995401.HKD","LU0882574055.USD","LU0689472784.USD","LU1923622614.USD","LU0211326839.USD","LU2491050154.USD","LU0061474960.USD","LU0081259029.USD","LU1267930813.SGD","LU0052756011.USD","LU2089984988.USD","LU0158827781.USD","LU2210150020.SGD","LU1066051225.USD","LU2089283258.USD","LU2543165471.USD","LU1923623000.USD","IE00B5TLWC47.USD","LU1267930573.SGD","LU2552382058.USD","SG9999001176.SGD","LU1732799900.SGD","LU1718418525.SGD","LU2360032135.SGD","LU1791710400.SGD","IE00BFTCPJ56.SGD","LU1291159041.SGD","LU1074936037.SGD","LU1003077747.HKD","LU2095319765.USD","LU1823568750.SGD","BK4561","LU0738911758.USD","IE00B19Z3581.USD","LU0107464264.USD","BK4548","LU2089284900.SGD","LU2324357040.USD","IE00B775H168.HKD","SG9999017495.SGD","LU1691799644.USD","IE00BN29S564.USD","LU2491050071.SGD","LU0251142724.SGD","BK4581","SG9999001424.SGD","LU1035773651.USD","LU1989772923.USD","LU0472753341.HKD","BK4505","LU0477156953.USD","LU0792757196.USD","LU0109392836.USD","WDAY","SG9999014880.SGD","LU0265550946.USD","BK4154","IE00B19Z9505.USD","IE00B19Z9P08.USD","LU0417517546.SGD","IE00B19Z8W00.USD"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.abcellera.com","stockEarnings":[{"period":"1week","weight":0.0116},{"period":"1month","weight":0.115},{"period":"3month","weight":-0.0359},{"period":"6month","weight":-0.2192},{"period":"1year","weight":0.4542},{"period":"ytd","weight":0.0205}],"compareEarnings":[{"period":"1week","weight":-0.015},{"period":"1month","weight":-0.0429},{"period":"3month","weight":-0.0286},{"period":"6month","weight":0.0074},{"period":"1year","weight":0.2011},{"period":"ytd","weight":-0.0288}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"AbCellera Biologics Inc. builds an engine for antibody drug discovery and development. Its engine discovers antibodies from natural immune responses, which are pre-enriched for antibodies. The company had discovery programs that are either completed, in progress, or under contract with partners. It has a research collaboration and license agreement with Eli Lilly and Company; and a research collaboration with Confo Therapeutics for the discovery of therapeutic antibody candidates targeting two undisclosed GPCR targets. The company was incorporated in 2012 and is headquartered in Vancouver, Canada.","yearOnYearQuotes":[{"month":1,"riseRate":0.666667,"avgChangeRate":0.002724},{"month":2,"riseRate":0,"avgChangeRate":-0.119779},{"month":3,"riseRate":0.166667,"avgChangeRate":-0.059327},{"month":4,"riseRate":0.2,"avgChangeRate":-0.104908},{"month":5,"riseRate":0.6,"avgChangeRate":-0.032152},{"month":6,"riseRate":0.4,"avgChangeRate":0.119513},{"month":7,"riseRate":0.6,"avgChangeRate":0.046684},{"month":8,"riseRate":0.4,"avgChangeRate":-0.080936},{"month":9,"riseRate":0.6,"avgChangeRate":0.036664},{"month":10,"riseRate":0.6,"avgChangeRate":0.00539},{"month":11,"riseRate":0.6,"avgChangeRate":-0.007841},{"month":12,"riseRate":0.2,"avgChangeRate":-0.030878}],"exchange":"NASDAQ","name":"AbCellera Biologics","nameEN":"AbCellera Biologics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"AbCellera Biologics(ABCL),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest AbCellera Biologics(ABCL) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"AbCellera Biologics,ABCL,AbCellera Biologics股票,AbCellera Biologics股票老虎,AbCellera Biologics股票老虎国际,AbCellera Biologics行情,AbCellera Biologics股票行情,AbCellera Biologics股价,AbCellera Biologics股市,AbCellera Biologics股票价格,AbCellera Biologics股票交易,AbCellera Biologics股票购买,AbCellera Biologics股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"AbCellera Biologics(ABCL),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest AbCellera Biologics(ABCL) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction